OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and advanced or metastatic triple negative breast cancer (TNBC), which is in Phase II clinical trials (KEYNOTE-890); ImmunoPulse IL-12 and KEYTRUDA in patients with advanced or metastatic melanoma that has completed Phase II clinical trials; and ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma, which has completed the Phase II clinical trials. In addition, the company is developing monotherapy biomarker study in patients with advanced or metastatic TNBC that has completed the Phase II clinical trials; and new DNA-encoded therapeutic candidates and tumor indications to treat deep visceral lesions, such as liver, lung, bladder, pancreatic, and other visceral lesions. It has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890 studies; a research collaboration with Duke University's Center for Applied Therapeutics to evaluate enhanced IL-12 DNA-plasmid; a research collaboration with Roswell Park Comprehensive Cancer Center to evaluate the use of Roswell Park's intravital microscopy and enhanced IL-12 DNA-plasmid; and collaboration with Providence Cancer Institute. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was founded in 2008 and is headquartered in Pennington, New Jersey.
IPO Year:
Exchange: NASDAQ
Website: oncosec.com
| Date | Price Target | Rating | Analyst |
|---|
BTIG Research initiated coverage of OncoSec Medical with a rating of Buy and set a new price target of $10.00
BTIG Research initiated coverage of OncoSec Medical with a rating of Buy and set a new price target of $10.00
PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and Blacktown Hospitals, Adil Daud, MD, from University of California San Francisco, Pablo Fernandez Peñas MD, PhD, FACD, from The University of Sydney, and Montaser Shaheen, MD, from the University of Arizona Cancer Center. The KOLs will discuss the clinical relevance of the updated KEYNOTE-695 data being presented in a poster at the SITC 2021 Annual Meeting. Specifically, the KEYNOTE-695 clinical trial enrolled meta
25-NSE - ONCOSEC MEDICAL Inc (0001444307) (Subject)
8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)
8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)
8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)
8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)
D - ONCOSEC MEDICAL Inc (0001444307) (Filer)
8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)
424B5 - ONCOSEC MEDICAL Inc (0001444307) (Filer)
8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)
8-K - ONCOSEC MEDICAL Inc (0001444307) (Filer)
PENNINGTON, N.J. and SAN DIEGO, April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of Robert H. Arch, Ph.D., as President and Chief Executive Officer. Dr. Arch was previously Head of Research at Elpiscience Biopharma, Ltd. from October 2019 to June 2021, and Head of the Liver Disease Department at China Novartis Institutes for BioMedical Research from February 2017 to October 2019. Robert's leadership roles have been focused on shaping strong teams and b
PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer, today announced the appointment of George Chi as Chief Financial Officer. Mr. Chi joins the Company from THPlasma, where he served as Chief Executive Officer since July 2020 and helped found the company's plasma collection business and establish regular commercial sales. Prior to joining THPlasma, Mr. Chi served as Chief Financial Officer of CASI Pharmaceuticals, Inc. ("CASI"), a biopharmaceutical company
PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian Leuthner, formerly Chief Operating Officer, has been appointed Interim Chief Executive Officer, effective June 25, 2021. Mr. O' Connor is also stepping down from his seat on the Board of Directors. "Under Dan's leadership over the past four years, OncoSec has transformed itself into the leading intra-tumoral cancer immunotherapy Company," said Margaret Dalesandro, Ph.D., Chair of the Board of Directors at OncoSec. "Dan operationally drove several value-creating clinical programs with the Comp
PENNINGTON, N.J. and SAN DIEGO, June 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice President of Product Engineering, effective June 14, 2021. Mr. Silverman, an engineering management veteran, brings to OncoSec extensive global industry experience spanning more than 20 years, in the development, manufacturing and scale up of Medical Devices including electroporation and gene delivery equipment for the delivery of DNA drugs in support of cancer and vaccine research. For more than five years, Mr. Silverman served as Vice President at Ichor Medical Systems, Inc., an industry leader f
PENNINGTON, N.J. and SAN DIEGO, May 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M. Schinagl, Ph.D., a biotech industry veteran with over 20 years of experience, as Vice President of Program and Alliance Management, effective May 17, 2021. "We are thrilled to welcome Dr. Schinagl to OncoSec's management team as the company continues to make progress in the development of our lead product candidate, TAVO™," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec. "As we actively seek opportunities through strategic partnerships and uphold our mission to bring transformative solution
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical Development effective February 18, 2021. "It is with great pleasure that we welcome Dr. O'Keeffe to OncoSec in her new role during a critical time of growth for the company," said Sandra Aung, Ph.D., Senior Vice President and Chief Clinical Development Officer. "At OncoSec, our mission is to bring safe and effective therapeutic options to patients who need it most. Having had the opportunity of previously w
4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
3 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
3 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
3 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
4 - ONCOSEC MEDICAL Inc (0001444307) (Issuer)
EWING, N.J. and SAN DIEGO, May 18, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the closing of its previously announced registered direct offering of 1,408,384 shares of its common stock, at a purchase price of $0.945 per share, priced at-the-market under Nasdaq rules. The Company also issued in a concurrent private placement unregistered warrants to purchase up to an aggregate of 1,408,384 shares of common stock. The warrants have an exercise price of $0.82 per sh
EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,408,384 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.945 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent
EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced a Type C meeting held with the US Food and Drug Administration (FDA) on May 15, 2023. The purpose of the meeting was to discuss the trial design for a planned randomized, open-label Phase 2 clinical trial in patients with high-risk, resectable melanoma to evaluate the neoadjuvant treatment combination of the Company's tavokinogene telseplasmid, a plasmid encoding human interleukin 12 (IL-12
EWING, N.J. and SAN DIEGO, April 27, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the receipt of $3.49 million in tax credit certificates from the New Jersey Economic Development Authority (NJEDA). The tax credit certificates are offered to qualified companies through the NJEDA's Technology Business Tax Certificate Transfer Program, which enables eligible technology and biotechnology companies based in New Jersey to sell unused net operating losses (NOLs) and research
EWING, N.J. and SAN DIEGO, April 11, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced the closing of its previously announced registered direct offering of 1,582,932 shares of its common stock, at a purchase price of $1.25 per share, priced at-the-market under Nasdaq rules. The Company also issued in a concurrent private placement unregistered warrants to purchase up to an aggregate of 1,582,932 shares of common stock. The warrants have an exercise price of $1.12 per s
EWING, N.J. and SAN DIEGO, April 10, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 1,582,932 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.25 per share (or common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. The Company has also agreed to issue in a concurrent
EWING, N.J. and SAN DIEGO, April 3, 2023 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the Company or OncoSec), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient's immune system to target cancer cells and eradicate disease, today announced primary endpoint data from the Phase 2 KEYNOTE-695 clinical trial. This global, open-label single-arm trial is evaluating TAVO™-EP, OncoSec's proprietary interleukin 12 (IL–12) encoding plasmid delivered by intratumoral electroporation, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with unresectable or metastatic (Stage III/IV) melanoma who had confi
PENNINGTON, N.J. and SAN DIEGO, Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced that Robert Arch, Ph.D., President and CEO of OncoSec, will be participating at the RHK Capital Disruptive Growth Conference in New York City. The RHK Capital Disruptive Growth Conference will feature leading C-suite executives and senior management of approximately 30 growth-oriented and disruptive companies to meet with seasoned institutional investors, accredited investors, rep
PENNINGTON, N.J. and SAN DIEGO, Nov. 30, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing intratumoral immunotherapies to stimulate the patient's own immune system to target and eradicate cancer, today announced the pricing of its "reasonable best efforts" public offering of 1,166,667 shares of common stock (or common stock equivalents) and Common Warrants to purchase 1,166,667 shares of common stock at a combined price of $3.00 per share, for aggregate gross proceeds of $3.5 million, before deducting placement agent fees and other offering expenses. The closing of the offering is expe
PENNINGTON, N.J. and SAN DIEGO, Nov. 15, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral immunotherapies that stimulate the patient's immune system to target cancer cells and eradicate disease, today announced early clinical data from an investigator-sponsored trial (IST) conducted by Dr. Ahmad Tarhini at the H. Lee Moffit Cancer Center & Research Institute. This IST is evaluating TAVO™, OncoSec's proprietary interleukin 12 (IL-12) encoding plasmid delivered by intratumoral electroporation (TAVO™-EP), in combination with intravenous nivolumab. Interim data were presented as a poster (
SC 13G/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13G - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13G - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13G - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13G/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13G/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13D/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13G/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)
SC 13G/A - ONCOSEC MEDICAL Inc (0001444307) (Subject)